A Phase 1 interventional study of JK07 and Matching Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Salubris Biotherapeutics Inc. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Salubris Biotherapeutics Inc (part of Shenzhen Salubris Pharmaceuticals Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,316th largest by enrollment of the 1,601 interventional ones that give a count, is one of 98 that started in 2020, is one of 118 in phase 1, and was the 1,444th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 313 · Phase 3 177 · Phase 4 139
First in 1983; this study’s year is marked. 98 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 65 across the 1,601 interventional studies, 150 across the 551 observational. Of the 1,510 that completed or were terminated, 629 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
746 of 2,157 have an industry lead sponsor. The 10 most frequent:
This study is registered under Salubris Biotherapeutics Inc, one of the names counted as Shenzhen Salubris Pharmaceuticals Co., Ltd.. Under that name alone:
Salubris Biotherapeutics Inc is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Shenzhen Salubris Pharmaceuticals Co., Ltd. has 4 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
136 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 136 to your calendar (.ics) → With an account.
Among the 2,157 studies in Heart Failure with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF ≤40%.
Initially 5 cohorts are planned with the option to expand the study to a total of 7 cohorts. The size of the cohorts will range from 5 to 9 subjects. Each cohort will include one single active unblinded sentinel subject receiving a single IV dose of JK07 prior to randomized single dose administration of JK07 or placebo [3:1] in the remainder of the cohort.
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in HF subjects 18 to 80 years of age with LVEF ≤40%. Subjects must have been maintained on an optimal HF medical regimen for at least 2 months prior to enrollment and remain on the same treatment regimen throughout the course of the study, per the 2017 ACC/AHA/HFSA) treatment guidelines.
At screening, eligible subjects will undergo a physical examination, 2-dimensional transthoracic echocardiography (2D-TTE), ECG assessment, blood sampling for laboratory parameters, and urine testing. Safety assessments at screening will include hematology, biochemistry, coagulation, liver, and thyroid function.
Subjects will be observed in the hospital on continuous telemetry from the time of hospital admission until shortly before discharge approximately 48 hours later. During this time, they will additionally have safety labs, vital signs, PK and biomarker samples collected, and ECGs and 2D-TTEs performed.
Only a single dose of the investigational product will be administered and only a single hospital admission is planned per subject during the study. Subjects will complete follow-up visits through 180 days after administration of the investigational product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
5. ≥18 kg/m2 and ≤45 kg/m2. 6. Screening ≥9.0 g/dL, ≥100 K/mL, ≥1500/mL. 7. Able and willing to use adequate until the end of the study.
8. Capable of providing informed consent and to comply with the protocol.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of JK07 administered by intravenous infusion over 60 minutes
Drug: JK07
Single dose of placebo administered by intravenous infusion over 60 minutes
Drug: Matching Placebo
Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Vehicle control
Incidence and Severity of Treatment-emergent Adverse Events [Safety and Tolerability]
All safety information is collected and evaluated.
Time frame: Screening to 30 days
AUC(0-last) of JK07
Area under the concentration (time curve to the last quantifiable concentration) from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.
Time frame: Baseline to 60 days
Cmax of JK07
Maximum concentration from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.
Time frame: Baseline to 60 days
t1/2 of JK07
Half-life from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.
Time frame: Baseline to 60 days
Left Ventricular Ejection Fraction (LVEF)
2D-transthoracic echocardiography-derived LVEF
Time frame: Screening to 180 days
| Milestone | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo |
|---|---|---|---|---|
| Started | 4 | 4 | 3 | 3 |
| Completed | 4 | 3 | 3 | 3 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
All safety information is collected and evaluated.
| number of events | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo |
|---|---|---|---|---|
| Treatment emergent AEs | 4 | 3 | 8 | 2 |
| SAEs | 0 | 0 | 1 | 0 |
Area under the concentration (time curve to the last quantifiable concentration) from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.
| h*ng/mL | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 |
|---|---|---|---|
| AUC(0-last) of JK07 | 5310 ± 80.6 | 34400 ± 2.9 | 139000 ± 15.1 |
2D-transthoracic echocardiography-derived LVEF
| % of LVEF | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo |
|---|---|---|---|---|
| Day 1 - pre dose | 34 (29 to 36) | 28 (21 to 32) | 25 (17 to 37) | 31 (28 to 37) |
| Day 1 - 6 hrs post dose | 37 (34 to 39) | 30.5 (19 to 40) | 31 (23 to 35) | 33.7 (29 to 43) |
| Day 2 | 39.8 (37 to 44) | 28.8 (21 to 41) | 30.7 (20 to 39) | 32.3 (32 to 33) |
| Day 7 | 38.5 (29 to 51) | 33.5 (26 to 40) | 28 (21 to 37) | 27.3 (23 to 31) |
| Day 15 | 42.5 (34 to 53) | 34.5 (28 to 40) | 28.3 (22 to 35) | 31 (27 to 38) |
| Day 30 | 40.8 (33 to 49) | 33 (25 to 38) | 28.7 (20 to 38) | 32.7 (29 to 39) |
| Day 60 | 38.5 (34 to 46) | 35.3 (28 to 44) | 30 (21 to 39) | 29.3 (22 to 33) |
| Day 90 | 37 (30 to 51) | 36 (21 to 47) | 27 (16 to 39) | 25 (21 to 28) |
| Day 135 | 36 (22 to 46) | 31.7 (26 to 39) | 32 (27 to 37) | 22 (19 to 25) |
| Day 180 | 36 (33 to 40) | 38.7 (30 to 52) | 32.3 (24 to 44) | 33.7 (31 to 36) |
Maximum concentration from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.
| ng/mL | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 |
|---|---|---|---|
| Cmax of JK07 | 497 ± 44.3 | 1680 ± 20.9 | 5170 ± 13.8 |
Half-life from blood samples taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60.
| h | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 |
|---|---|---|---|
| t1/2 of JK07 | 8.11 ± 42.7 | 10.95 ± 10.8 | 18.32 ± 8.2 |
Collected over Entire study duration (~180 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JK07 - Cohort 1 | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| JK07 - Cohort 2 | 1/4 (25%) | 0/4 (0%) | 3/4 (75%) |
| JK07 - Cohort 3 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Matching Placebo | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Event | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo |
|---|---|---|---|---|
| Upper Extremity WeaknessMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Event | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo |
|---|---|---|---|---|
| Night sweatsSkin and subcutaneous tissue disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Muscle painMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Bilateral shoulder painMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Urinary tract infectionInfections and infestations | 0/4 | 0/4 | 1/3 | 0/3 |
| Brachial neuritis of both upper extremitiesNervous system disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Elevated creatinineInvestigations | 0/4 | 0/4 | 1/3 | 0/3 |
| Myalgia and arthralgiaMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Neuropathy exacerbationNervous system disorders | 0/4 | 0/4 | 1/3 | 0/3 |
| Elevated liver enzymesInvestigations | 0/4 | 0/4 | 0/3 | 1/3 |
| Left arm nerve painNervous system disorders | 0/4 | 0/4 | 0/3 | 1/3 |
This was an ascending dose phase 1 trial. Participants were enrolled in an ascending fashion lower to higher doses of JK07.
| Age, Categorical(Participants) | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 1 | 3 | 10 |
| >=65 years | 0 | 2 | 2 | 0 | 4 |
| Age, Continuous(years) | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo | Total |
|---|---|---|---|---|---|
| Mean | 53.3 ± 10.9 | 61.3 ± 9.74 | 61.0 ± 14.93 | 54.3 ± 5.13 | 57.4 ± 10.14 |
| Sex: Female, Male(Participants) | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 1 | 4 |
| Male | 4 | 2 | 2 | 2 | 10 |
| Race (NIH/OMB)(Participants) | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 2 |
| White | 4 | 3 | 3 | 2 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | JK07 - Cohort 1 | JK07 - Cohort 2 | JK07 - Cohort 3 | Matching Placebo | Total |
|---|---|---|---|---|---|
| United States | 4 | 4 | 3 | 3 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Jun 2023, 32 months.
Results were first posted in Jul 2025, 2 years 1 month after primary completion.
Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 32 months is above that.
Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JK07
Salubris Biotherapeutics Inc →